If you have been recently diagnosed with early-stage invasive breast cancer, there is a possibility that you may not require chemotherapy. CanAssist Breast test provides additional information about the tumour. Along with the existing pathology report, this test result lets you know the likelihood of cancer returning at a distant site after surgery and whether you are likely to benefit from chemotherapy or not.
Knowing the patient's recurrence risk allows the doctors to devise treatment plans that are in-tune with the prognosis, thereby, maintaining an optimal balance between the benefits and side-effects of chemotherapy.
The CanAssist Breast risk score ranges from 0 -100. A risk score cut off of 15.5 is used to classify patients as low-risk (score 15.5 or less) for distant recurrence. The maximum probability of distant recurrence for low-risk patients for five years is 9% which means that you have less than a 1 in 10 chances of distant cancer recurrence.